1-9 of 9
Kay B. Delasalle
Close
Sort by
Journal Articles

A Phase II Trial Of Bortezomib-Rituximab Followed By Autologous Stem Cell Harvest (SCH) and Cladribine-Cyclophosphamide-Rituximab (2CdA-Cy-Rit) Consolidation As Primary Therapy Of Waldenström's Macroglobulinemia (WM)

Sheeba K. Thomas, M.D., Tamara M Haygood, M.D., Muzaffar H. Qazilbash, MD, A. Georgina Melendez, M.D., Roxana Galvis, Kay B Delasalle, B.S., Lei Feng, M.S., Tiffany A. Richards, M.S., Felipe Samaniego, M.D., M.P.H, Luhua Wang, M.D., Jatin J. Shah, M.D., Robert Z. Orlowski, M.D., Ph.D., Donna M. Weber, M.D.
Journal: Blood
Blood (2013) 122 (21): 4396.
https://doi.org/10.1182/blood.V122.21.4396.4396
Published: 2013
Journal Articles

Impact of Rituximab On the Treatment of Waldenström's Macroglobulinemia (WM).

Sheeba K. Thomas, MD, Kay B Delasalle, B.S., Jatin J. Shah, M.D., Luhua Wang, M.D., Robert Z. Orlowski, M.D., Ph.D., Donna M. Weber, M.D.
Journal: Blood
Blood (2012) 120 (21): 2734.
https://doi.org/10.1182/blood.V120.21.2734.2734
Published: 2012
Journal Articles

Feasibility of Hematopoietic Stem Cell Collection and Cryopreservation in Waldenstrom's Macroglobulinemia

Dilshad Khan, MBBS, Krina Patel, MD, Sheeba K. Thomas, MD, Donna M. Weber, M.D., Kay B Delasalle, B.S., Chitra M. Hosing, M.D., Uday R. Popat, M.D., Qaiser Bashir, MD, Nina Shah, MD, Simrit Parmar, M.D., Richard E. Champlin, Muzaffar Qazilbash, M.D.
Journal: Blood
Blood (2012) 120 (21): 4128.
https://doi.org/10.1182/blood.V120.21.4128.4128
Published: 2012
Journal Articles

Prognostic Factors for Survival After 2-CdA-Based Therapy for Symptomatic Waldenström Macroglobulinemia (WM) Stratify Patients Into Low- and High-Risk Groups.

Sheeba K Thomas, M.D., Lei Feng, M.S., Kay B Delasalle, B.S., Michael Wang, M.D., Jatin J Shah, M.D., Robert Z Orlowski, M.D., Ph.D., Raymond Alexanian, M.D., Donna M Weber, M.D.
Journal: Blood
Blood (2009) 114 (22): 1668.
https://doi.org/10.1182/blood.V114.22.1668.1668
Published: 2009
Journal Articles

Curability of Multiple Myeloma.

Kay B Delasalle, BS, Luhua Wang, MD, Donna Weber, MD, Sergio A. Giralt, MD, Sheeba Thomas, MD, Jatin Shah, MD, Beverly Handy, MD, Robert Z. Orlowski, MD, PhD, Raymond Alexanian, M.D.
Journal: Blood
Blood (2009) 114 (22): 3864.
https://doi.org/10.1182/blood.V114.22.3864.3864
Published: 2009
Journal Articles

Incidence of Transformation to Large Cell Lymphoma and to Second Malignancies in Symptomatic Patients with Waldenstrom’s Macroglobulinemia (WM) Treated with Cladribine (2-CdA) Combination Induction Therapy

Ronjay Rakkhit, MD, Kay B Delasalle, B.S., Maria B. Gavino, R.N., Sheeba K. Thomas, Meletios A Dimopoulos, MD, Fredrick B. Hagemeister, MD, Maria Alma Rodriguez, MD, Peter McLaughlin, MD, Raymond Alexanian, MD, Donna M. Weber, MD
Journal: Blood
Blood (2008) 112 (11): 3065.
https://doi.org/10.1182/blood.V112.11.3065.3065
Published: 2008
Journal Articles

Survival Outcomes of Patients Receiving Thalidomide-Dexamethasone for Previously Untreated Multiple Myeloma.

Sheeba K. Thomas, MD, Sergio A. Giralt, M.D., Michael Wang, M.D., Kay B. Delasalle, B.S., Maria Gavino, R.N., Kim Rankin, L.V.N., Raymond Alexanian, M.D., Donna M. Weber, M.D.
Journal: Blood
Blood (2006) 108 (11): 3569.
https://doi.org/10.1182/blood.V108.11.3569.3569
Published: 2006
Journal Articles

VTD (Velcade, Thalidomide, Dexamethasone) as Primary Therapy for Newly-Diagnosed Multiple Myeloma.

Luhua M. Wang, MD, Donna M. Weber, MD, Kay B. Delasalle, Raymond Alexanian, MD
Journal: Blood
Blood (2004) 104 (11): 210.
https://doi.org/10.1182/blood.V104.11.210.210
Published: 2004
Journal Articles

2-Chlorodeoxyadenosine (2-CdA) and Cyclophosphamide (Cy) Alone or in Combination with Rituximab (Rit) for Previously Untreated Waldenstrom’s Macroglobulinemia (WM).

Donna M. Weber, MD, Michael Wang, MD, Kay B. Delasalle, BS, Maria Gavino, RN, Raymond Alexanian, MD
Journal: Blood
Blood (2004) 104 (11): 1476.
https://doi.org/10.1182/blood.V104.11.1476.1476
Published: 2004